A patient can be treated with itraconazole if both of the following are present:
(1) the patient is at low risk for invasive pulmonary aspergillosis
(2) adequate serum levels can be expected (reliable oral absorption, no drug interactions)
A patient can treated with conventional amphotericin B if:
(1) the risk of invasive pulmonary disease is high or there is documented infection
(2) the patient cannot be treated with itraconazole
(3) the patient is not at risk for severe nephrotoxicity or cardiotoxicity
(4) the patient does not develop severe toxicity while receiving conventional amphotericin B therapy
A patient can be treated with a lipid formulation of amphotericin B if:
(1) the patient is at risk for severe toxicity from conventional amphotericin B therapy or
(2) the patient develops severe toxicity during conventional amphotericin B therapy
